Vincerx Pharma, Inc. Common Stock
VINC
VINC was delisted on the 22nd of April, 2025.
34 hedge funds and large institutions have $10.8M invested in Vincerx Pharma, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 11 reducing their positions, and 4 closing their positions.
3% less funds holding
Funds holding: 35 → 34 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
31% less capital invested
Capital invested by funds: $15.7M → $10.8M (-$4.87M)
55% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$1.41M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$38.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$16.6K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$16.3K |
| 5 |
SRC
Sage Rhino Capital
Menlo Park,
California
|
+$16K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
-$1.94M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$477K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$473K |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$293K |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
-$47.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| $25.1K | +$660 | +34 | +3% |
|
|
XT
27
XTX Topco
George Town,
Cayman Islands
| $17.4K | +$16.3K | +842 | New |
|
|
GW
28
GW & Wade
Wellesley,
Massachusetts
| $11K | – | – | – |
|
|
LP
29
LMR Partners
London,
United Kingdom
| $10.1K | -$47.4K | -2,445 | -83% |
|
|
HCM
30
Hollencrest Capital Management
Newport Beach,
California
| $10.1K | – | – | – |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| $7.25K | +$2.91K | +150 | +72% |
|
32
UBS Group
Zurich,
Switzerland
| $5.79K | +$5.57K | +287 | New |
|
33
Barclays
London,
United Kingdom
| $2.58K | – | – | – |
|
34
Wells Fargo
San Francisco,
California
| $127 | – | – | – |
|
35
Fidelity Investments
Boston,
Massachusetts
| $6 | – | – | – |
|
36
Qube Research & Technologies (QRT)
London,
United Kingdom
| $4 | – | – | – |
|
|
AAA
37
Affinity Asset Advisors
New York
| – | -$1.94M | -74,639 | Closed |
|
|
BBA
38
Baker Bros. Advisors
New York
| – | -$293K | -11,279 | Closed |
|
39
Two Sigma Investments
New York
| – | -$13.6K | -522 | Closed |
|
40
JP Morgan Chase
New York
| – | -$512 | -20 | Closed |
|
VINC Hedge Fund Activity: Q3 2023 in Review
34 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q3 2023, worth a combined $10.8M — down 31% from $15.7M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of VINC and 3 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 5 added.
The largest buyer was Bank of America, adding an estimated $1.41M. The largest seller was Affinity Asset Advisors, exiting entirely with an estimated $1.94M sold.
- 34 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q3 2023, down from 35 in Q2 2023.
- Funds reported $10.8M of Vincerx Pharma, Inc. Common Stock stock for Q3 2023, down 31% quarter-over-quarter.
- 3 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q3 2023 and 4 closed out, a net change of -1 holder.
- The largest Vincerx Pharma, Inc. Common Stock buyer in Q3 2023 was Bank of America, an estimated $1.41M added.
- The largest Vincerx Pharma, Inc. Common Stock seller in Q3 2023 was Affinity Asset Advisors, an estimated $1.94M sold.
Based on aggregated 13F filings for Q3 2023.